AARTIDRUGSAarti Drugs Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

₹418.00

▼ 1.02%

Decent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)3,815.10

P/E19.56

P/B2.46

PEG—

ROE %13.36

ROCE %11.40

Debt / Equity0.37

EPS21.37

Revenue Growth %6.40

Profit Growth %-12.00

Dividend Yield %0.48

Promoter Holding %60.17

FII Holding %11.11

DII Holding %—

Beta0.35

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on AARTIDRUGS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 71%

The picture

• Debt/Equity: 0.37
• Promoter holding: 60.2%
• Valuation vs sector: P/E 19.6 vs sector 38.6
• RSI: 70
• MACD: bullish
• Price vs EMA21: above

Bull case

• Debt/Equity: 0.37
• Promoter holding: 60.2%
• Valuation vs sector: P/E 19.6 vs sector 38.6
• RSI: 70

Bear case

• Revenue growth: 6.4% YoY
• Profit growth: -12.0% YoY
• Golden cross setup: SMA50 below SMA200
• Volume: 0.8x 20-day average

Key risks

• Revenue growth: 6.4% YoY
• Profit growth: -12.0% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)

₹418.00

Stop Loss

₹385.24

risk 7.8%

Target 1 (1.5R)

₹467.14

+11.8%

Target 2 (3R)

₹516.27

+23.5%

Support (20d)

₹368.55

Resistance (52w)

₹561.04

Risk : Reward

1 : 1.5 → 1 : 3

risking ₹32.76/share

ATR (volatility)

₹13.10

avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹13.10). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental

Technical

Momentum

Risk (safety)

Peers — Pharma

About

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.